Axellia enters U.S. OTC arena
This article was originally published in The Tan Sheet
Executive SummaryDanish firm Axellia Pharmaceuticals will use its newly acquired majority stake in Phoenix Global Supply Group to launch private-label OTCs in the U.S. and Canada. The Copenhagen-based firm manufactures anti-infective active pharmaceutical ingredients and intends to provide APIs, such as bacitracin and polymyxin B sulfate, for Phoenix to use in topical first-aid products. Axellia said May 18 its investment in White Plains, N.Y.-based Phoenix allows the "significant expansion of Axellia's presence in the international pharmaceutical market.
You may also be interested in...
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.
Amid the ongoing spread of the coronavirus outbreak, China turns to novel and repurposed antiviral drugs but also courts traditional medicines to ease public fear over the largely unknown threat.
With Pataday Once Daily Relief (0.2% olopatadine) and Twice Daily (0.1%), Alcon adds allergy treatment to its lineup of OTC drops indicated for dry eye and redness. “Obviously, eye allergy will become a much bigger part of the portfolio for us,” says US vision care GM Sean Clark.